Answers are grounded in this paper and cite their sources.
Ocular surface dysfunction is a common but underrecognized complication of vitreoretinal surgery. This study investigated whether adjunctive topical cyclosporine A (CsA) 0.05% improves postoperative ocular surface recovery compared with hyaluronic acid (HA) 0.15% alone in patients undergoing pars plana vitrectomy. In this prospective, examiner-masked, randomized controlled trial, 54 patients with dry eye disease undergoing 25-gauge pars plana vitrectomy were randomized 1:1 to receive topical HA 0.15% alone or HA 0.15% plus CsA 0.05%. Ocular surface parameters were assessed at baseline and postoperative day 1, week 1, month 1, and month 3. The primary outcome was the National Eye Institute (NEI) corneal staining score at postoperative month 3, analyzed by analysis of covariance (ANCOVA) adjusting for baseline score and combined phacovitrectomy status. Secondary outcomes included tear break-up time (TBUT), Schirmer I test, Oxford corneal staining score, tear matrix metalloproteinase-9 (MMP-9) grade, conjunctival hyperemia grade, meiboscore, and Ocular Surface Disease Index (OSDI) score. A total of 50 patients (25 per group; 26 men and 24 women) completed the study. At postoperative month 3, the adjusted NEI corneal staining score was significantly lower in the HA 0.15% + CsA 0.05% group than in the HA 0.15% group (adjusted mean difference −2.53, 95% confidence interval [CI] −3.73 to −1.34; p < 0.001). A linear mixed-effects model confirmed a significant group-by-time interaction ( p = 0.030). Exploratory subgroup analyses showed within-subgroup differences favoring HA 0.15% + CsA 0.05% in patients with longer operation time, diabetes mellitus, and no sclerotomy suturing. A significant treatment-by-operation time interaction was observed, but not for diabetes or sclerotomy suturing status. TBUT was transiently longer in the HA 0.15% + CsA 0.05% group at postoperative week 1 ( p = 0.018); no other secondary outcomes differed significantly between groups. Adjunctive topical CsA 0.05% was associated with significantly greater improvement in NEI corneal staining score, an indicator of corneal epithelial integrity, at 3 months after vitrectomy, whereas most secondary outcomes, including patient-reported symptoms, did not differ between groups. These findings provide preliminary evidence supporting a potential role for adjunctive CsA in postoperative corneal epithelial recovery and warrant confirmation in larger trials. Clinical Research Information Service (CRIS) identifier, KCT0012351; registered 29 July 2026, retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: